Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Amgen Looking At Sourcing Erythropoietin From Indian Companies?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - As pharmaceutical companies the world over gear up for the emerging multi-billion dollar biosimilars opportunity in the U.S., biotechnology major Amgen is said to be looking at sourcing a part of its erythropoietin raw material requirements from Indian companies. Amgen sells the nearly $6 billion blockbuster anemia drug under brand name Epogen

You may also be interested in...



After Launching First Pegylated GCSF, Intas Biopharma Examines Technology For Pegylated Erythropoietin

MUMBAI - Ahmedabad, India-based biotech firm Intas Biopharma is looking at commencing research on a generic form of pegylated erythropoietin

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1132553

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel